6YKI
| Crystal structure of YTHDC1 with compound DHU_DC1_092 | Descriptor: | SULFATE ION, YTHDC1, ~{N}-ethyl-2-[(2~{S},5~{R})-5-methyl-2-phenyl-morpholin-4-yl]ethanamine | Authors: | Bedi, R.K, Huang, D, Wiedmer, L, Caflisch, A. | Deposit date: | 2020-04-06 | Release date: | 2020-07-15 | Last modified: | 2024-01-24 | Method: | X-RAY DIFFRACTION (1.3 Å) | Cite: | Structure-based design of ligands of the m6A-RNA reader YTHDC1 Eur J Med Chem Rep, 5, 2022
|
|
4ZZJ
| SIRT1/Activator/Substrate Complex | Descriptor: | (3S)-1,3-dimethyl-N-[3-(1,3-oxazol-5-yl)phenyl]-6-[3-(trifluoromethyl)phenyl]-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide, Ac-p53, CARBA-NICOTINAMIDE-ADENINE-DINUCLEOTIDE, ... | Authors: | Dai, H. | Deposit date: | 2015-05-22 | Release date: | 2015-07-15 | Last modified: | 2023-11-15 | Method: | X-RAY DIFFRACTION (2.7403 Å) | Cite: | Crystallographic structure of a small molecule SIRT1 activator-enzyme complex. Nat Commun, 6, 2015
|
|
4ZZH
| SIRT1/Activator Complex | Descriptor: | (4S)-N-[3-(1,3-oxazol-5-yl)phenyl]-7-[3-(trifluoromethyl)phenyl]-3,4-dihydro-1,4-methanopyrido[2,3-b][1,4]diazepine-5(2H)-carboxamide, NAD-dependent protein deacetylase sirtuin-1, ZINC ION | Authors: | Dai, H. | Deposit date: | 2015-05-22 | Release date: | 2015-07-15 | Last modified: | 2024-03-06 | Method: | X-RAY DIFFRACTION (3.1001 Å) | Cite: | Crystallographic structure of a small molecule SIRT1 activator-enzyme complex. Nat Commun, 6, 2015
|
|
4ZZI
| SIRT1/Activator/Inhibitor Complex | Descriptor: | (3S)-1,3-dimethyl-N-[3-(1,3-oxazol-5-yl)phenyl]-6-[3-(trifluoromethyl)phenyl]-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide, 4-(4-{2-[(methylsulfonyl)amino]ethyl}piperidin-1-yl)thieno[3,2-d]pyrimidine-6-carboxamide, NAD-dependent protein deacetylase sirtuin-1, ... | Authors: | Dai, H. | Deposit date: | 2015-05-22 | Release date: | 2015-07-15 | Last modified: | 2023-09-27 | Method: | X-RAY DIFFRACTION (2.7346 Å) | Cite: | Crystallographic structure of a small molecule SIRT1 activator-enzyme complex. Nat Commun, 6, 2015
|
|
3QUP
| |
1LB0
| NMR Structure of HIV-1 gp41 659-671 13-mer peptide | Descriptor: | GP41 | Authors: | Biron, Z. | Deposit date: | 2002-04-01 | Release date: | 2002-12-04 | Last modified: | 2024-05-22 | Method: | SOLUTION NMR | Cite: | A Monomeric 3(10)-Helix Is Formed in Water by a 13-Residue Peptide
Representing the Neutralizing Determinant of HIV-1 on gp41(,). Biochemistry, 41, 2002
|
|
6FGP
| |
4L3Q
| Crystal structure of glucokinase-activator complex | Descriptor: | 6-{3-[(1-methyl-1H-imidazol-2-yl)sulfanyl]phenyl}pyridin-2(1H)-one, Glucokinase, alpha-D-glucopyranose | Authors: | Gajiwala, K.S, Filipski, K.J. | Deposit date: | 2013-06-06 | Release date: | 2013-07-24 | Last modified: | 2023-09-20 | Method: | X-RAY DIFFRACTION (2.7 Å) | Cite: | Pyrimidone-based series of glucokinase activators with alternative donor-acceptor motif. Bioorg.Med.Chem.Lett., 23, 2013
|
|
3S41
| Glucokinase in complex with activator and glucose | Descriptor: | Glucokinase, N,N-dimethyl-5-({2-methyl-6-[(5-methylpyrazin-2-yl)carbamoyl]-1-benzofuran-4-yl}oxy)pyrimidine-2-carboxamide, SODIUM ION, ... | Authors: | Liu, S. | Deposit date: | 2011-05-18 | Release date: | 2011-09-14 | Last modified: | 2023-09-13 | Method: | X-RAY DIFFRACTION (2.18 Å) | Cite: | Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus MEDCHEMCOMM, 2, 2011
|
|
2MZX
| CCR5-ECL2 helical structure, residues Q186-T195 | Descriptor: | C-C chemokine receptor type 5 | Authors: | Abayev, M, Anglister, J. | Deposit date: | 2015-02-26 | Release date: | 2015-04-22 | Last modified: | 2024-05-15 | Method: | SOLUTION NMR | Cite: | An extended CCR5 ECL2 peptide forms a helix that binds HIV-1 gp120 through non-specific hydrophobic interactions. Febs J., 282, 2015
|
|